Royal Bank Of Canada Eiger Bio Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.21 - $0.43 $89 - $182	424 Added 45.2%	1,362 $0
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.93 $35 - $116	-125 Reduced 11.76%	938 $0
Q2 2023 Aug 14, 2023	SELL	$0.55 - $1.26 $1,116 - $2,557	-2,030 Reduced 65.63%	1,063 $0
Q1 2023 May 15, 2023	SELL	$0.89 - $2.52 $3,380 - $9,570	-3,798 Reduced 55.12%	3,093 $2,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $4,925 - $36,120	4,829 Added 234.19%	6,891 $8,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $5,683 - $9,090	941 Added 83.94%	2,062 $16,000
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $7,964 - $14,300	-1,596 Reduced 58.74%	1,121 $7,000
Q1 2022 May 16, 2022	SELL	$3.84 - $9.74 $16,773 - $42,544	-4,368 Reduced 61.65%	2,717 $22,000
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $12,369 - $19,787	2,416 Added 51.75%	7,085 $37,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $11,536 - $15,715	1,727 Added 58.7%	4,669 $31,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $9.23 $23,006 - $27,154	2,942 New	2,942 $25,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.